AstraZeneca reportedly struck a U.S. drug‑pricing agreement following the administration’s MFN/onshoring talks, while separate reporting flagged a Novo Nordisk manufacturing site in Bloomington, Indiana, for noncompliance. AstraZeneca’s deal follows Pfizer’s earlier engagement with the White House and reflects industry moves to negotiate pricing and onshoring commitments amid regulatory pressure. Separately, the FDA classified Novo Nordisk’s recently acquired Indiana contract manufacturing plant as officially noncompliant, an action that could delay approvals for drugs produced there and has already affected multiple makers. Novo Nordisk said it is working with the agency and customers to remediate deficiencies and improve processes. The twin developments highlight how political and manufacturing risks are converging: pricing negotiations and plant compliance issues are creating operational uncertainty across supply chains and regulatory timelines.